Transcatheter Aortic Valve Replacement was Edwards Lifesciences’s largest product and service line in fiscal 2025, bringing in $4.49B of $6.07B (74%).
| Product and Service | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $3.52B | $4.11B | $4.49B | ||||||||||||||
| Transcatheter Heart Valve Therapy | — | — | — | ||||||||||||||
| Salesrevenuenet | — | — | — | ||||||||||||||
| Revenue, Net | — | — | — | ||||||||||||||
| Surgical Structural Heart | $829.70M | $981.30M | $1.03B | ||||||||||||||
| Surgical Heart Valve Therapy | — | — | — | ||||||||||||||
| Critical Care | — | — | — | ||||||||||||||
| Net Sales | — | — | — | ||||||||||||||
| Transcatheter Mitral & Tricuspid Therapies | $116.10M | $352.10M | $550.60M | ||||||||||||||
| Total | $4.46B | $5.44B | $6.07B |
Edwards Lifesciences brought in $6.07B from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 11.5% from $5.44B in fiscal 2024. Transcatheter Aortic Valve Replacement was the largest at $4.49B (74.0%), ahead of Surgical Structural Heart at $1.03B (17.0%) and Transcatheter Mitral & Tricuspid Therapies at $550.60M (9.1%).
Compared with fiscal 2024, Transcatheter Mitral & Tricuspid Therapies grew fastest, up 56.4% to $550.60M. Every line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these lines grew from $4.46B to $6.07B, a compound annual growth rate of 10.8%. Transcatheter Aortic Valve Replacement's share of the total fell from 78.8% to 74.0%.
United States was Edwards Lifesciences’s largest segment in fiscal 2025, bringing in $3.54B of $6.07B (58%).
| Segment | FY 2012 | FY 2014 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.63B | $3.21B | $3.54B | ||||||||
| Europe | $1.04B | $1.32B | $1.52B | ||||||||
| Rest Of World | $436.00M | $572.00M | $652.30M | ||||||||
| Japan | $359.50M | $339.80M | $354.70M | ||||||||
| Total | $4.46B | $5.44B | $6.07B |
Edwards Lifesciences brought in $6.07B from its four segments in fiscal 2025, the year ended December 31, 2025. That was up 11.5% from $5.44B in fiscal 2024. United States was the largest at $3.54B (58.4%), ahead of Europe at $1.52B (25.0%) and Rest Of World at $652.30M (10.8%). The remaining segment, Japan, brought in $354.70M.
Compared with fiscal 2024, Europe grew fastest, up 14.8% to $1.52B. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments grew from $4.46B to $6.07B, a compound annual growth rate of 10.8%. United States' share held steady at about 58.4%.
United States was Edwards Lifesciences’s largest region in fiscal 2021, bringing in $2.96B of $5.23B (57%).
| Geography | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.06B | $2.53B | $2.52B | $2.96B | ||||||||||
| Salesrevenuenet | — | — | — | — | ||||||||||
| Revenue, Net | — | — | — | — | ||||||||||
| Europe | $885.10M | $941.20M | $973.60M | $1.19B | ||||||||||
| Net Sales | — | — | — | — | ||||||||||
| Japan | $396.80M | $444.70M | $460.10M | $528.90M | ||||||||||
| Rest Of World | $385.60M | $429.40M | $435.80M | $550.20M | ||||||||||
| Total | $3.72B | $4.35B | $4.39B | $5.23B |
Edwards Lifesciences brought in $5.23B from its four regions in fiscal 2021, the year ended December 31, 2021. That was up 19.3% from $4.39B in fiscal 2020. United States was the largest at $2.96B (56.6%), ahead of Europe at $1.19B (22.7%) and Rest Of World at $550.20M (10.5%). The remaining region, Japan, brought in $528.90M.
Compared with fiscal 2020, Rest Of World grew fastest, up 26.3% to $550.20M. Every region above 2% of revenue grew. From fiscal 2018 to 2021, combined revenue from these regions grew from $3.72B to $5.23B, a compound annual growth rate of 12.0%. United States' share of the total rose from 55.2% to 56.6%.
Edwards Lifesciences (EW) reports its revenue by product and service, by segment and by geography. In fiscal 2025, Transcatheter Aortic Valve Replacement was its largest product and service line, bringing in $4.49B (74.0% of the total), followed by Surgical Structural Heart at $1.03B (17.0%).
Transcatheter Aortic Valve Replacement was Edwards Lifesciences' largest product and service line in fiscal 2025, bringing in $4.49B, or 74.0% of the $6.07B total across its three product and service lines.
United States was Edwards Lifesciences' largest segment in fiscal 2025, bringing in $3.54B, or 58.4% of the $6.07B total across its four segments.
United States was Edwards Lifesciences' largest region in fiscal 2021, bringing in $2.96B, or 56.6% of the $5.23B total across its four regions.
Among Edwards Lifesciences' product and service lines that make up at least 2% of revenue, Transcatheter Mitral & Tricuspid Therapies grew fastest in fiscal 2025, up 56.4% from $352.10M to $550.60M.
Every figure comes from Edwards Lifesciences' annual financial filings, as reported. Each line keeps the name Edwards Lifesciences gives it, and years follow its fiscal calendar.
Edwards Lifesciences' revenue by product and service goes back to fiscal 2008, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.